The Broker Innovation Lab celebrates brokers and other benefits stakeholders who have embraced the changing marketplace to position themselves and their business for future success
Perrigo, which sought FDA approval for an over-the-counter version last summer after the Supreme Court's ruling that overturned Roe v. Wade, expects a final decision by the end of summer in the U.S.
Under mounting pressure, Novo Nordisk plans to cut list prices for insulin products by up to 75%, now the latest drugmaker to take such a step following a California lawsuit accusing drugmakers of driving up costs.